WHAT IS THE FUTURE OF PROSTATE‐SPECIFIC ANTIGEN FOR THE EARLY DETECTION OF PROSTATE CANCER?

BJU InternationalVolume 102, Issue 2 p. 157-158 WHAT IS THE FUTURE OF PROSTATE-SPECIFIC ANTIGEN FOR THE EARLY DETECTION OF PROSTATE CANCER? Robert Getzenberg, Robert Getzenberg Urology, Johns Hopkins Medicine, Baltimore, MD, USASearch for more papers by this author Robert Getzenberg, Robert Getzenberg Urology, Johns Hopkins Medicine, Baltimore, MD, USASearch for more papers by this author First published: 28 June 2008 https://doi.org/10.1111/j.1464-410X.2008.07694.xCitations: 2 Robert Getzenberg, Urology, Johns Hopkins Medicine, Marburg 121 600 N Wolfe St Baltimore, MD 21287, USA. e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Gau J-T. Prostate-specific antigen (PSA). Biosynthetic and secretory pathways, and its role in growth regulation of prostate epithelial cells in vitro [PhD Dissertation]. United States, Pennsylvania: University of Pittsburgh, 1998 Google Scholar 2 Khan MA, Partin AW, Rittenhouse HG et al. Evaluation of pro-prostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0–10.0 ng/mL. J Urol 2003; 170: 723–6 10.1097/01.ju.0000086940.10392.93 CASPubMedWeb of Science®Google Scholar 3 Zheng SL, Sun J, Wiklund F et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910–9 10.1056/NEJMoa075819 CASPubMedWeb of Science®Google Scholar 4 Leman ES, Cannon GW, Trock BJ et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007; 69: 714–20 10.1016/j.urology.2007.01.097 PubMedWeb of Science®Google Scholar 5 Sokoll LJ, Ellis W, Lange P et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008; 389: 1–6 10.1016/j.cca.2007.11.003 CASPubMedWeb of Science®Google Scholar 6 Tan BK, Tan LK, Yu K et al. Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res 2008; 14: 461–9 10.1158/1078-0432.CCR-07-0999 CASPubMedWeb of Science®Google Scholar 7 Bianchi F, Nuciforo P, Vecchi M et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007; 117: 3436–44 10.1172/JCI32007 CASPubMedWeb of Science®Google Scholar 8 Carter HB, Kettermann A, Warlick C et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178: 2359–64 10.1016/j.juro.2007.08.039 PubMedWeb of Science®Google Scholar Citing Literature Volume102, Issue2July 2008Pages 157-158 ReferencesRelatedInformation